SciELO - Scientific Electronic Library Online

 
vol.147 issue1Healthcare of transgenders by non-specialists in ChileDependency in Chile. Advances and challenges author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista médica de Chile

Print version ISSN 0034-9887

Abstract

ENRIQUEZ, Andrés; BARANCHUK, Adrian  and  CORBALAN, Ramón. Management of bleeding associated with direct oral anticoagulants: update on reversal strategies. Rev. méd. Chile [online]. 2019, vol.147, n.1, pp.73-82. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872019000100073.

Direct oral anticoagulants (DOACs), including the direct thrombin inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban have at least comparable efficacy as vitamin K antagonists along with a better safety profile, reflected by a lower incidence of intracranial hemorrhage. Specific reversal agents have been developed in recent years. Namely, idarucizumab, a specific antidote for dabigatran, is currently approved in most countries. Andexanet, which reverses factor Xa inhibitors, has been recently approved by the FDA, and ciraparantag, a universal antidote targeted to reverse all DOACs, is still under investigation. In this review we provide an update on the pharmacology of DOACs, the risk of hemorrhagic complications associated with their use, the measurement of their anticoagulant effect and the reversal strategies in case of DOAC-associated bleeding.

Keywords : Anticoagulants; Hemorrhage; Risk Factors.

        · text in Spanish     · Spanish ( pdf )